Core Viewpoint - The approval of VELSIPITY for the treatment of moderate to severe active ulcerative colitis (UC) in adults marks a significant milestone for the company and aligns with its 2030 development strategy [1] Group 1: Company Developments - The company’s stock rose over 5% in the afternoon trading session, currently up 3.4% at HKD 40.18, with a trading volume of HKD 151 million [1] - The National Medical Products Administration (NMPA) of China has approved the new drug application for VELSIPITY, which is intended for patients who have inadequate response, loss of response, or intolerance to traditional therapies or biological agents [1] - The company plans to actively prepare for the commercialization of VELSIPITY and aims to expedite the availability of this therapy to domestic patients while pushing for its inclusion in the national medical insurance catalog [1] Group 2: Strategic Goals - The approval of VELSIPITY is a crucial part of the company's 2030 development strategy, which emphasizes a dual approach of "BD collaboration + self-research" to create certain value through commercialization and growth value through research and development [1] - The company aims to strengthen its core therapeutic area advantages, advance innovative drug research and commercialization, and establish a sustainable growth model as a global innovative biopharmaceutical enterprise [1]
云顶新耀午后曾涨超5% 维适平新药上市申请获国家药监局批准